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Severe HypertriglyceridemiaWith Pancreatitis
Thirteen Years’ TreatmentWith Lomitapide
FrankM. Sacks, MD; Maxine Stanesa, PA-C; Robert A. Hegele, MD
R ecurrent pancreatitis is a severe and potentially fatalcomplication of hypertriglyceridemia.1-3 A triglycer-ide level greater than 2000 mg/dL is defined as “very
severe hypertriglyceridemia”4 because these levels can cause
pancreatitis.1-4 A fasting triglyceride level of 1000 to 2000
mg/dL is defined as “severe hypertriglyceridemia” and car-
ries a risk of pancreatitis because after eating, triglyceride lev-
elsmayriseabove2000mg/dL. (Toconvert triglycerides tomil-
limoles per liter, multiply by 0.0113.)
Severeandveryseverehypertriglyceridemiacanbecaused
by several genetic defects that impairmetabolismby lipopro-
tein lipase of triglycerides in chylomicrons and very low den-
sity lipoproteins (VLDL).5 This is also called familial chylomi-
cronemia (type 1 dyslipidemia). Treatments that increase
metabolism of triglycerides by lipoprotein lipase, such as fi-
brates or omega-3 fatty acids, are ineffective. Microsomal tri-
glyceride transfer protein (MTP) transfers triglycerides and
other lipids to apolipoprotein B48 in the enterocyte and apo-
lipoprotein B100 in the hepatocyte, a necessary step to start
the assembly of the lipid-protein complex in the enterocyte
that will become a chylomicron or in the hepatocyte to be-
come a VLDL or low-density lipoprotein (LDL).6 Genetic defi-
ciency ofMTP causes abetalipoproteinemia, characterizedby
very lowplasma levels of triglycerides.6 Thus,MTP inhibitors
could substantially lower plasma triglyceride levels by inhib-
iting the formation and secretion of triglyceride-rich lipopro-
teins.
Report of a Case
Clinical History Before TreatmentWithMTP Inhibition
The patient was first hospitalized for pancreatitis at age 15
years. She was treated with a low-fat diet; gemfibrozil, 1200
mg; omega-3 fatty acids; and niacin, singly or in combina-
tion; without benefit. She had had pancreatitis during each
of her 3 pregnancies, at ages 23, 33, and 34 years, 1 of which
ended in miscarriage. For the next 11 years, she experienced
chronic abdominal pain, and recurrent pancreatitis requir-
ing 12 hospitalizations, in spite of maximal dietary and drug
treatment. The mean (SD) triglyceride level on hospital
admission, not necessarily fasting, was 3570 (1619) mg/dL
(median, 3179 mg/dL for 12 hospitalizations). During the last
1 to 2 years of this period, the patient’s chronic abdominal
IMPORTANCE Recurrent pancreatitis is a potentially fatal complication of severe
hypertriglyceridemia. Genetic defects and lifestyle risk factors may render this condition
unresponsive to current treatments.
OBSERVATIONS We report this first case of long-termmanagement of intractable near-fatal
recurrent pancreatitis secondary to severe hypertriglyceridemia by a novel use of lomitapide,
an inhibitor of microsomal triglyceride transfer protein, recently approved for treatment of
familial homozygous hypercholesterolemia. The patient had been hospitalizedmany times
for pancreatitis since age 15 years. Her serum triglyceride level averaged 3900mg/dL while
she received therapy with approved lipid drugs. She is homozygous for a codingmutation
(P234L) in lipoprotein lipase, leaving her unable to metabolize triglycerides in chylomicrons
and very low density lipoproteins (VLDL). Lomitapide reduces the secretion of chylomicrons
and VLDL. Lomitapide, which was started when she was 44 years old after near-fatal
pancreatitis, lowered her fasting triglyceride level from greater than 3000mg/dL to amean
(SD) of 903 (870) mg/dL while she received 30mg/d and to 524 (265) mg/dL while she
received 40mg/d; eliminated chronic abdominal pain; and prevented pancreatitis. However,
fatty liver, present before treatment, progressed to steatohepatitis and fibrosis after 12 to 13
years.
CONCLUSIONS AND RELEVANCE Lomitapide prevented pancreatitis in severe intractable
hypertriglyceridemia but at a potential long-term cost of hepatotoxicity.
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pain worsened in intensity and duration, seriously damag-
ing her ability to live normally. At age 44 years, she experi-
enced a near-fatal episode of pancreatitis complicated by
hypotension and acute respiratory distress syndrome that
required intubation. A pancreatectomy was recommended
as preventive treatment but was deferred to permit addi-
tional attempts at medical treatment. Three months later,
pancreatitis returned, and she was admitted to the hospital
with a serum triglyceride level of 4840 mg/dL.
Laboratory and Clinical Evaluations Before Treatment
With Lomitapide
The patient’s fasting serum triglyceride levels were usually
higher than 2000 mg/dL. Her plasma was grossly lipemic.
Additional findings were lipemia retinalis, anemia (hemato-
crit, 26%-34%), thrombocytopenia (platelet count, 100 000
cells/μL), and leucopenia (white blood cell count, 2000-
4000/μL). A bone marrow biopsy specimen taken at age 31
years showed 40% replacement with macrophage-foam
cells. Abdominal ultrasonographic findings repeatedly
showed fatty liver and splenomegaly. Computed tomo-
graphic (CT) scans showed no hepatomegaly or other liver
abnormality. Serum alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) levels were usually within
reference range. The patient did not have diabetes mellitus;
her body weight was normal, with a body mass index, calcu-
lated as weight in kilograms divided by height in meters
squared, of 21 to 22; and results from thyroid and renal tests
were normal. She rarely drank alcoholic beverages. (To con-
vert hematocrit to a proportion of 1, multiply by 0.01; to
convert platelets to ×109/μL, multiply by 1.0; to convert
white blood cell count to ×109/μL, multiply by 0.001.)
Genetic and Phenotypic Diagnosis
Direct sequencing of the patient’s genomic DNA revealed ho-
mozygosity for the coding missense mutation (P234L) in the
LPL gene producing noncatalytically active lipoprotein li-
pase (LpL).7 The LPL P234L mutation has been found in Chi-
nese persons in China8 and in French Canadians.7 The pa-
tient’sethnicity isChinese.Nootherpotential culpritmutations
were found incoding regions, intron-exonboundariesandpro-
moters of APOC2, APOA5, LMF1, and GPIHBP1 genes.
HerplasmaLpLmassconcentrationswereelevated (mono-
mers, 1010ng/mL [reference range, 150-300ng/mL]; anddim-
ers, 150 ng/mL [reference range, 50-100 ng/mL]),9 consistent
with the diagnosis of functionally defective LpL. The plasma
apolipoproteinCII concentrationwas approximately 10 times
the reference range (35 mg/dL [reference range, 1.6-4.2 mg/
dL]).
The patient’smean serum fasting lipid levels just prior to
lomitapide treatmentwere as follows: triglyceride level, 3109
mg/dL; LDL cholesterol (LDL-C) level, 63 mg/dL; high-
density lipoprotein cholesterol (HDL-C) level, 29 mg/dL; and
apolipoprotein B level, 745mg/dL (reference range, <120mg/
dL). Apolipoprotein B100 and B48 levels were both elevated.
(To convert LDL-C and HDL-C to millimoles per liter, multi-
ply by0,0259; to convert apolioprotein to gramsper liter,mul-
tiply by 0.01.)
Oneof thepatient’s brothers also has severe hypertriglyc-
eridemia and recurrent pancreatitis. Five other siblings have
moderatehypertriglyceridemiabutwithoutpancreatitis, sug-
gesting that at least someof themmaybeheterozygous for the
LPL P234L mutation. Her parents’ lipid levels are unknown.
TreatmentWithMTP Inhibition
An emergency investigational newdrug use and institutional
review board approval for lomitapide were granted. Written
informed consent was received. On June 7, 1999, other lipid-
loweringtherapywasstopped,andtreatmentwas initiatedwith
lomitapide,whichwas the first use of anMTP inhibitor for hy-
pertriglyceridemia.
The lomitapide dosewas titrated to balance the triglycer-
ide-lowering effect with avoidance of diarrhea presumably
caused by fat malabsorption (Figure 1). During the first year
of treatment, the patient’s fasting triglyceride level while re-
ceiving the 12.5mg/ddose averaged 2110mg/dL;while receiv-
ing the alternating 12.5 mg/d and 25mg/d dose regimen, 1416
mg/dL; and while receiving the 25 mg/d dose, 371 mg/dL
(Figure 1). A 6-month trial of adding fenofibrate, 200mg/d, to
lomitapide, 12.5 mg/d, in an attempt to control the hypertri-
glyceridemia with a lower dose of lomitapide was a failure
(Figure 2). In 2009, Aegerion reformulated lomitapide into
20-mg and 40-mg capsules. The patient’s fasting triglyceride
levels during treatmentwith the 20mg/d dose averaged 1604
mg/dL;during treatmentwithalternating20mg/dand40mg/d
dose regimen, 903mg/dL; andduring treatmentwith40mg/d
dose, 524 mg/dL (Figure 2). Her hematocrit level range in-
creased from a range of 26% to 34% to a range of 38% to 40%
after the fifth year.
To date, the patient has been treated with lomitapide for
13 years. She has had 3 brief uncomplicated hospitalizations
Figure 1. Serum Fasting Triglyceride Concentrations at Baseline (B) and
During the First Year of TreatmentWith Lomitapide
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The dose of lomitapide was adjusted to balance efficacy and tolerability. The
patient’s triglyceride level when receiving 12.5 mg/d averaged 2110mg/dL,
when receiving the alternating dose regimen of 12.5 mg/d and 25mg/d
averaged 1416mg/dL, and when receiving 25mg/d averaged 371 mg/dL.
Discontinued indicates temporary cessation of lomitapide. (To convert
triglycerides to millimoles per liter, multiply by 0.0113.)
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for pancreatitis during the third, fourth, and seventh years of
treatment associatedwith eitherhavingno lomitapideorhigh
dietary fat intake during visits to her family in China.
Hepatic Toxicity of Lomitapide
The patient’s serumALT andAST levels during the initial 6 to
7 years of lomitapide treatment were usually within refer-
ence range, increasing thereafter (Figure 3).Her alkalinephos-
phatase levels were within reference range before treatment
and through 12years of lomitapide treatment. In the 13thyear,
the alkaline phosphatase level increased to 130 and 143U (up-
per limit of reference range, 125 U) (to convert alkaline phos-
phatase tomicrokatalsper liter,multiplyby0.0167).Her serum
bilirubinandalbumin levelswerewithin referencerangebefore
andduring lomitapide treatment.Ultrasonographic examina-
tionsshowedfatty liver, and findings fromhepaticCTandmag-
netic resonance image scans were normal. Results of a liver
biopsy at 1 year showedmarked steatosiswithoutnecrosis, in-
flammation, fibrosis, or stainable iron; at 3 years showed se-
vere microvesicular and macrovesicular steatosis, minimal
lobular inflammation, mild cholestasis, without necrosis, fi-
brosis, or stainable iron; at 5 years showed marked predomi-
nantly macrovesicular steatosis without inflammation or fi-
brosis, and trace amounts of stainable iron; and at 8.5 years
showedmarked predominantlymacrovesicular steatosis and
mild steatohepatitis but no clinically significant fibrosis or
stainable iron. The results from the most recent biopsy at 13
years showed severemixed large- and small-droplet steatosis
involving more than 66% of the core biopsy (NASH activity
score, 3); frequentballooningdegeneration (score, 2);mildpor-
tal and septal andmild to focally moderate lobular mixed in-
flammation (score, 2); andportal, septal, and sinusoidal fibro-
sis (at least stage3 fibrosis, focallyearly stage3-4); andnegative
results from an iron stain.
Progression of fatty liver to hepatitis and fibrosis pre-
sents a therapeutic dilemma.10 In lipoprotein lipase defi-
ciency, largenascent triglyceride-rich chylomicrons andVLDL
cannot be metabolized to smaller lipoproteins that can pass
through the sinusoidal endothelial cell fenestrations to thehe-
patocytes that clear themfromthecirculation.11 Instead, these
large lipoproteins are takenupby the reticuloendothelial sys-
tem in the liver, spleen, and bonemarrow. Prior to lomitapide
treatment, the patient didnot have an increased serum trans-
aminase levelorhepatomegaly.Thefatty liver repeatedly found
on ultrasonography could have represented lipid-laden sinu-
soidal macrophages (Kupfer cells), suggested by their preva-
lence in the bone marrow. A liver biopsy was not performed
before lomitapide treatment. In contrast, inhibition of he-
patic MTP decreases a principal means that hepatocytes use
to reduce their fat content.12 TheMTP inhibition inhypercho-
Figure 2. Serum Fasting Triglyceride (TG) Concentrations During Years 2 to 13 of TreatmentWith Lomitapide
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Each episode of pancreatitis (P) is defined as brief uncomplicated
hospitalization associated with not taking the drug or exceptionally high dietary
fat intake (The 2 P’s close to each other are simply 2 pancreatitis episodes that
occurred at the times indicated on the x-axis). At year 4, a 6-month trial of
adding fenofibrate, 200mg/d, to lomitapide, 12.5 mg/d, to try to control the
hypertriglyceridemia on a lower dose of lomitapide was a failure. The patient’s
mean serum TG level was 3175mg/dL (range, 2525-3880mg/dL; N = 4 TG
tests) with the combination, compared with 2345mg/dL (range, 1041-3600
mg/dL; N = 6 TGmeasurements) during treatment with lomitapide, 12.5 mg/d.
This time period is indicated by vertical gray columns. In the 10th year,
lomitapide was reformulated into 20- and 40-mg capsules. Themean (SD) TG
levels during treatment with 20mg/d was 1604 (1030) mg/dL (median, 1331
mg/dL; N = 13 TGmeasurements); during treatment with the alternating dose
of 20mg/d and 40mg/d, 903 (870) mg/dL (median, 703mg/dL; N = 10 TG
measurements); and during treatment with the 40-mg/d dose, 524 (265)
mg/dL (median, 542mg/dL; N = 4 TGmeasurements). B indicates baseline. (To
convert TG tomillimoles per liter, multiply by 0.0113.)
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lesterolemia increases liver transaminases and hepatic fat
content.13,14 Therefore, the hepatic pathophysiologic char-
acteristics of lomitapide toxicity differ from those of lipo-
protein lipase deficiency, and it is possible that the 2 sepa-
rate effects may adversely interact. No other patient has
been treated with lomitapide for more than 5 years, and
thus the long-term effects of the drug in lipoprotein lipase
deficiency as well as in familial hypercholesterolemia need
to be studied carefully.
Discussion
Now that lomitapide is available in theUnited States for treat-
ment of familial homozygous hypercholesterolemia, physi-
ciansmayconsider it to treat pancreatitis causedby severehy-
pertriglyceridemia. However, lomitapide is not approved for
this “off-label” use, and it may be available only on a named
patient compassionate use basis with approval of the manu-
facturer and the relevant health authorities and ethics com-
mittees. We suggest these criteria: (1) pancreatitis associated
with severe hypertriglyceridemia, (2) failure of intensive diet
and drug treatment to prevent episodes of pancreatitis, and
(3) no active hepatitis or hepatic fibrosis.
We do not recommend using lomitapide in patients who
have severe hypertriglyceridemia without pancreatitis be-
causemanyof themneverdeveloppancreatitis.A recent clini-
cal case series reported that 16% of patients who had triglyc-
eride levels higher than 1772 mg/dL had pancreatitis.15
Maximum efforts to encourage dietary adherence must be
made, especially because dietary fat will make the lomi-
tapide less effective at a given dose and more prone to cause
diarrhea.We emphasize that we used lomitapide in a desper-
ateclinical situation inwhich thepatientatany timecouldhave
a fatal attack of pancreatitis. If physicians choose to use lomi-
tapide in such patients, they must report their results so ex-
periencewill accumulate tounderstand thebenefits and long-
term risks.
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